NASDAQ:ERAS Erasca (ERAS) Stock Price, News & Analysis $1.38 -0.07 (-4.83%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$1.38 0.00 (0.00%) As of 07/3/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Erasca Stock (NASDAQ:ERAS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Erasca alerts:Sign Up Key Stats Today's Range$1.39▼$1.4750-Day Range$1.08▼$1.6352-Week Range$1.01▼$3.45Volume867,633 shsAverage Volume1.67 million shsMarket Capitalization$390.94 millionP/E RatioN/ADividend YieldN/APrice Target$4.57Consensus RatingBuy Company Overview Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California. Read More Erasca Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreERAS MarketRank™: Erasca scored higher than 62% of companies evaluated by MarketBeat, and ranked 387th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingErasca has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageErasca has only been the subject of 2 research reports in the past 90 days.Read more about Erasca's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Erasca are expected to grow in the coming year, from ($0.73) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Erasca is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Erasca is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErasca has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Erasca's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.05% of the float of Erasca has been sold short.Short Interest Ratio / Days to CoverErasca has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.Change versus previous monthShort interest in Erasca has recently decreased by 2.51%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldErasca does not currently pay a dividend.Dividend GrowthErasca does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.05% of the float of Erasca has been sold short.Short Interest Ratio / Days to CoverErasca has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.Change versus previous monthShort interest in Erasca has recently decreased by 2.51%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News SentimentN/A News SentimentErasca has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Erasca this week, compared to 2 articles on an average week.Search Interest2 people have searched for ERAS on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Erasca to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Erasca insiders have not sold or bought any company stock.Percentage Held by Insiders14.40% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.78% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Erasca's insider trading history. Receive ERAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter. Email Address ERAS Stock News HeadlinesUSA News Group: Oncology Innovation Just Hit a Turning Point -- Here's What to WatchJune 30, 2025 | finanznachrichten.deFDA clears Erasca’s new cancer drug applicationsJune 3, 2025 | uk.investing.comBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change. July 5 at 2:00 AM | Crypto 101 Media (Ad)Erasca Announces Clearance Of IND Application By FDA For ERAS-4001June 3, 2025 | nasdaq.comErasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001June 2, 2025 | globenewswire.comErasca to Present at Upcoming Investor Conferences in JuneMay 29, 2025 | globenewswire.comErasca Reports First Quarter 2025 Business Updates and Financial ResultsMay 13, 2025 | globenewswire.comErasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash RunwayMay 13, 2025 | globenewswire.comSee More Headlines ERAS Stock Analysis - Frequently Asked Questions How have ERAS shares performed this year? Erasca's stock was trading at $2.51 at the start of the year. Since then, ERAS stock has decreased by 45.0% and is now trading at $1.38. How were Erasca's earnings last quarter? Erasca, Inc. (NASDAQ:ERAS) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01. When did Erasca IPO? Erasca (ERAS) raised $262 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share. How do I buy shares of Erasca? Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Erasca own? Based on aggregate information from My MarketBeat watchlists, some other companies that Erasca investors own include Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY), American Water Works (AWK), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/13/2025Today7/04/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ERAS CIK1761918 Webwww.erasca.com Phone858-465-6511FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$4.57 High Stock Price Target$6.00 Low Stock Price Target$3.00 Potential Upside/Downside+231.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$161.65 million Net MarginsN/A Pretax MarginN/A Return on Equity-36.56% Return on Assets-31.08% Debt Debt-to-Equity RatioN/A Current Ratio12.35 Quick Ratio12.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.50 per share Price / Book0.92Miscellaneous Outstanding Shares283,290,000Free Float242,494,000Market Cap$390.94 million OptionableOptionable Beta1.05 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ERAS) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.